Conjugated Antisense APO(a) Dosing for Lower Lp(a) Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies to treat cardiovascular disease by directly targeting apo(a) levels have been limited, and there is a need for optimized treatment methods using ISIS 681257 to potently and selectively reduce Apo(a) levels in humans while minimizing patient exposure to unnecessary doses, particularly in patients at risk for cardiovascular events due to chronically elevated plasma Lp(a) levels.
Innovation Solution
Administering the oligomeric compound ISIS 681257 to patients with established cardiovascular disease at a dosage of about 75 mg to 85 mg, either once a month or every four weeks, to reduce Lp(a) levels and lower the risk of cardiovascular events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic strategies targeting apo(a) are used, then cardiovascular disease treatment is achieved, but treatment efficacy is limited and requires frequent dosing
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of antisense compounds through conjugation with GalNAc clusters and incorporating specific nucleoside modifications (2'-O-methoxyethyl, phosphorothioate linkages). These structural parameter changes enhance compound potency and pharmacokinetic properties, enabling once-monthly or once-every-two-months dosing while maintaining effective apo(a) reduction
Solution Approach 2:
The patent uses composite materials by combining multiple chemical modifications within a single antisense compound structure. The compounds integrate GalNAc conjugation with specific nucleoside modifications (5-10-5 gapmer motif containing 2'-O-methoxyethyl modified nucleosides and phosphorothioate linkages), creating a multi-functional molecule that simultaneously achieves target binding, RNA degradation, and enhanced pharmacokinetics
2Reliability
If higher doses of antisense compounds are administered to reduce Apo(a) levels, then treatment potency is improved, but patient exposure and treatment burden increase
Solution Approach 1:
The patent applies parameter changes by optimizing the chemical structure of the antisense compound through conjugation with GalNAc clusters and incorporating specific nucleoside modifications. These structural modifications enhance the compound's potency and pharmacokinetic properties, allowing for reduced dosing (75-85 mg once monthly or every 4 weeks) while maintaining effective apo(a) reduction, thereby decreasing patient exposure and treatment burden
3Stability of the object's composition
If more frequent administration is used to maintain Apo(a) reduction, then therapeutic effect is sustained, but treatment burden and cost increase
Solution Approach 1:
The patent applies parameter changes by modifying the pharmacokinetic parameters of the antisense compound through conjugation with GalNAc clusters and incorporating specific nucleoside modifications. These changes extend the compound's half-life and duration of action, enabling once-monthly or once-every-two-months dosing that maintains sustained therapeutic effect while reducing administration frequency and treatment burden
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ISIS 681257 significantly reduces Lp(a) levels, providing a favorable safety and tolerability profile, with reduced frequency of administration, lower overall treatment burden, and improved patient compliance, while achieving clinically significant reductions in cardiovascular risk markers.
Implementation Method 1
The principle behind antisense technology is that an antisense compound hybridizes to a target nucleic acid and modulates the amount, activity, and/or function of the target nucleic acid
Implementation Method 2
An example of modulation of RNA target function by degradation is RNase H-based degradation of the target RNA upon hybridization with a DNA-like antisense compound
Data Source
AI summary
The present disclosure is directed to methods of reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a). Specifically, a method of reducing the risk of a cardiovascular event in a patient who has established cardiovascular disease with conjugated antisense compound ISIS 681257 or a salt thereof.